A5031355003- HIV/AIDS drug development and treatment
- Pharmacological Effects and Toxicity Studies
- Antibiotics Pharmacokinetics and Efficacy
- HIV Research and Treatment
- Renal Transplantation Outcomes and Treatments
- Schizophrenia research and treatment
- Antimicrobial Resistance in Staphylococcus
- HIV/AIDS Research and Interventions
- Epilepsy research and treatment
- Drug Transport and Resistance Mechanisms
- Bipolar Disorder and Treatment
- HIV-related health complications and treatments
- Antibiotic Resistance in Bacteria
- Organ Transplantation Techniques and Outcomes
- Biochemical and Molecular Research
- Maternal Mental Health During Pregnancy and Postpartum
- Antifungal resistance and susceptibility
- Electroconvulsive Therapy Studies
- Neurological Complications and Syndromes
- Pharmaceutical studies and practices
- Bacterial Identification and Susceptibility Testing
- Pesticide Residue Analysis and Safety
- Transplantation: Methods and Outcomes
- Pharmacogenetics and Drug Metabolism
- Pneumocystis jirovecii pneumonia detection and treatment
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2023-2024
ASST Fatebenefratelli Sacco
2016-2023
Luigi Sacco Hospital
2010-2021
University of Milan
2011-2019
National Research Council
2011-2019
IRCCS Eugenio Medea
2014-2016
Ministero della Salute
2016
Istituti di Ricovero e Cura a Carattere Scientifico
2016
University of the Witwatersrand
2014
University of Perugia
2011
The immunosuppressive agent mycophenolic acid (MPA) is metabolized by uridine diphosphate glucuronosyltransferase 1A9 (UGT1A9) to 7-O-glucuronide (MPAG) and excreted multidrug resistance-associated protein 2 in the bile. By contrast, production of acyl MPAG, a minor MPA metabolite, was ascribed UGT2B7 UGT1A8. Several polymorphisms genes encoding for UGT1A9, MRP2 proteins have been described. However, their functional role vivo on metabolism remains poorly defined.A total 40 Caucasian kidney...
Abstract: Individualization of vancomycin dosing based on therapeutic drug monitoring (TDM) data is known to improve patient outcomes compared with fixed or empirical strategies. There increasing evidence support area-under-the-curve (AUC 24 )–guided TDM inform decisions for patients receiving therapy more than 48 hours. It acknowledged that there may be institutional barriers the implementation AUC -guided dosing, and additional effort required enable transition from trough-based -based...
Cyclosporine A (CsA) is a substrate of P-glycoprotein, an efflux transporter encoded by the ABCB1 gene. Compared with carriers wild-type gene, T allelic variants in exons 21 or 26 have reduced P-glycoprotein activity and, secondarily, increased intracellular concentration CsA; therefore, might be at risk for CsA-related adverse events. We evaluated associations between genotypes (in 12, 21, and 26) outcomes 147 renal transplant recipients who were receiving CsA-based immunosuppression...
Limited studies in healthy volunteers and HIV-1-infected patients have shown that raltegravir pharmacokinetics are characterized by high inter-patient variability. Only scanty data are, however, available on intra-patient The present study was designed to evaluate parallel the inter- variability of during routine therapeutic drug monitoring (TDM).Fifteen HIV-infected treated with highly active antiretroviral therapy containing 400 mg twice daily were included study. Pharmacokinetic...
Abstract Therapeutic drug monitoring (TDM) of antiepileptic drugs is widely used in clinical practice to optimise therapy, but it limited by technical problems and cost considerations. The aim the present study was: 1) validate a chromatographic method for concomitant determination levetiracetam, lamotrigine, ethosuximide, felbamate, rufinamide, zonisamide monohydroxycarbamazepine; 2) develop dried plasma spot (DPS) assessing its reliability against classical from plasma; 3) test...
Aim: Novel oral anticoagulants are characterized by a wide therapeutic window, yet the determination of their plasma–drug concentrations may be useful in some clinical conditions. Results: An LC–MS/MS method for analysis dabigatran, apixaban and rivaroxaban human plasma has been successfully developed validated. The samples from patients given other concomitant drugs revealed no significant interference. By reanalysis on anticoagulant therapy, we found percentage difference results between...
The introduction of mycophenolate mofetil has improved graft survival after organ transplantation; however, its use may be limited by important adverse effects. For overcoming these problems, an enteric-coated formulation sodium been developed, but pharmacokinetic data mycophenolic acid release from this are scanty.Pharmacokinetic studies in 32 kidney transplant recipients who were given the (n = 12) or 20) performed. profiles two formulations at months 6, 12, 18, and 24 transplantation...
Treatment with tenofovir sometimes leads to non-reversible kidney and/or bone diseases. Factors associated these drug-related adverse events are poorly characterized. Our objective was investigate such factors in patients treated long term daily tenofovir. One-hundred Caucasian HIV-positive basal creatinine clearance >80 mL/min for at least 6 months and one assessment of plasma trough concentrations were considered. Tenofovir-associated defined as the appearance pathological proteinuria,...
A new method using high-performance liquid chromatography coupled with ultra violet detection (HPLC-UV) was developed and validated for the simultaneous quantification of atazanavir, dolutegravir, darunavir, efavirenz, etravirine lopinavir, raltegravir, rilpivirine tipranavir in human plasma. For first time we reported here development validation an HPLC-UV assay to quantify frequently administered 9 antiretroviral compounds including dolutegravir rilpivirine. simple solid phase extraction...
Avibactam is a β-lactamase inhibitor that combined with aztreonam against Enterobacterales co-expressing serine- and metallo-β-lactamases (MBL). Optimal dosing of avibactam not well-defined in critically ill patients contingent on ceftazidime/avibactam product labelling.To identify pragmatic strategy for to maximize the probability target attainment (PTA).We conducted prospective observational pharmacokinetic study. Five blood samples were collected around fourth dose or assayed all three...
ABSTRACT The pharmacokinetics of raltegravir (RAL) in HIV patients is characterized by high interpatient/intrapatient variability. We investigated the potential contribution drug pharmaceutical formulation to RAL pharmacokinetics. first compared vivo for 67 whom was administered swallowing intact tablet with those obtained from 13 HIV-infected who chewed due difficulties. Subsequently, we evaluated vitro dissolution tablets under different conditions. In study, found that given chewing...
Abstract Background Intravenous fosfomycin (IVFOF) is gaining interest in severe infections. Its use may be limited by adverse events (AEs). Little experience exists on IVFOF therapeutic drug monitoring (TDM) real-life setting. Patients and methods Retrospective study of patients receiving for > 48 h at Policlinico Hospital (Milan, Italy) from 01/01/2019 to 01/01/2023. AEs associated graded CTCAE ≥ II were considered. Demographic clinical risk factors IVFOF-related analysed with simple...
A high-performance liquid chromatographic method for the determination of linezolid in human plasma was developed and validated. After precipitation proteins with perchloric acid, protein-free supernatant separated by isocratic reverse-phase chromatography on a X Bridge C18 column. The mobile phase consisted mixture phosphoric acid 0.05%: acetonitrile (75:25, v/v) flow rate 1 mL/min. column elute monitored at 254 nm. linear from 0.2 to 48 mg/L (mean r2 = 0.9996, n 10). observed intra-...
We have developed and validated a high-performance liquid chromatographic method for the simultaneous quantification, in human plasma, of dolutegravir, new immunodeficiency virus (HIV) integrase inhibitor, rilpivirine, novel HIV nonnucleoside reverse transcriptase inhibitor.An internal standard (quinoxaline) was added to plasma aliquots (500 μL), simple solid-phase extraction procedure applied. Chromatographic separation drugs achieved with gradient acetonitrile acetate buffer, an analytical...
Background: The dose of tenofovir alafenamide is reduced from 25 to 10 mg daily when given with boosting agents. However, such reduction has never been adopted for disoproxil fumarate (TDF). In this study, we aim quantify the effect cobicistat (COBI) both on concentrations and TDF durability in real life setting. Methods: HIV-positive patients receiving TDF-containing antiretroviral therapies at least 1 assessment plasma trough were included study. Univariate multivariate regression analyses...